John Mascarenhas, MD, and Joe Scandura, MD, PhD, discuss recent advances in the treatment of polycythemia vera (PV) and the impact on clinical practice.
September 15th 2023
Joe Scandura, MD, PhD, explains how a patient with polycythemia vera and driver mutations responds to interferon treatment.
Key opinion leaders discuss data on the use of ruxolitinib in patients with polycythemia vera.
September 22nd 2023
John Mascarenhas, MD, and Joe Scandura, MD, PhD, close their discussion by highlighting what to look forward to in the future of polycythemia vera treatment.